STAT+: Tortugas Neuroscience launches with hopes to develop drugs for brain disorders, other conditions
Tortugas Neuroscience, a new biotech startup, has launched with plans to develop drugs for brain disorders, specifically targeting schizophrenia and tinnitus, by licensing therapies from China's Jiangsu Hansoh and Japan's Eisai. The company has secured $106 million in funding to begin mid-stage trials in the U.S.
Tortugas Neuroscience's launch with a $106 million investment to test mid-stage trials in the U.S. for drugs licensed from Jiangsu Hansoh and Eisai represents a significant development opportunity in the biotech startup space, particularly for brain disorder treatments. This move highlights potential investment opportunities for those tracking advancements in precision medicine and pharmaceutical collaborations between Western startups and Asian drugmakers.